Nicotinamide Phosphoribosyltransferase
"Nicotinamide Phosphoribosyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the formation of nicotinamide mononucleotide (NMN) from nicotinamide and 5-phosphoribosyl-1-pyrophosphate, the rate-limiting step in the biosynthesis of the NAD coenzyme. It is also known as a growth factor for early B-LYMPHOCYTES, or an ADIPOKINE with insulin-mimetic effects (visfatin).
| Descriptor ID |
D054409
|
| MeSH Number(s) |
D08.811.913.400.725.575
|
| Concept/Terms |
Nicotinamide Phosphoribosyltransferase- Nicotinamide Phosphoribosyltransferase
- Phosphoribosyltransferase, Nicotinamide
- NAMPT Protein
- Pre-B-Cell Colony-Enhancing Factor
- Colony-Enhancing Factor, Pre-B-Cell
- Pre B Cell Colony Enhancing Factor
- Visfatin
- NAmPRTase
- NMN Pyrophosphorylase
|
Below are MeSH descriptors whose meaning is more general than "Nicotinamide Phosphoribosyltransferase".
Below are MeSH descriptors whose meaning is more specific than "Nicotinamide Phosphoribosyltransferase".
This graph shows the total number of publications written about "Nicotinamide Phosphoribosyltransferase" by people in this website by year, and whether "Nicotinamide Phosphoribosyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nicotinamide Phosphoribosyltransferase" by people in Profiles.
-
eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2025 Oct; 73(4):572-585.
-
Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia. PLoS One. 2025; 20(6):e0324443.
-
Contribution of membrane raft redox signalling to visfatin-induced inflammasome activation and podocyte injury. Aging (Albany NY). 2023 11 17; 15(22):12738-12748.
-
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2022 02 01; 24(2):229-244.
-
NAMPT maintains mitochondria content via NRF2-PPARa/AMPKa pathway to promote cell survival under oxidative stress. Cell Signal. 2020 02; 66:109496.
-
Podocyte NLRP3 Inflammasome Activation and Formation by Adipokine Visfatin. Cell Physiol Biochem. 2019; 53(2):355-365.
-
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology. 2018 09; 155(3):799-814.e13.
-
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown. FASEB J. 2018 07; 32(7):3583-3596.
-
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. 2016 08 28; 379(1):1-11.
-
Gene Expression-Based Predictive Models of Graft Versus Host Disease-Associated Dry Eye. Invest Ophthalmol Vis Sci. 2015 Jul; 56(8):4570-81.